Nektar Therapeutics/$NKTR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Ticker

$NKTR
Primary listing

Industry

Pharmaceuticals

Employees

61

ISIN

US6402683063

NKTR Metrics

BasicAdvanced
$368M
-
-$9.52
0.56
-

Bulls say / Bears say

B. Riley Securities initiated coverage of Nektar Therapeutics with a 'Buy' recommendation and a price target of $4.00, suggesting a potential upside of 250.88% from the current price. (marketbeat.com)
Nektar Therapeutics reported a net income of $7.26 million for the quarter ended December 31, 2024, marking a significant improvement from a net loss in the same quarter the previous year. (tradingview.com)
The company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata, indicating progress in its clinical pipeline. (prnewswire.com)
Nektar Therapeutics reported a quarterly revenue of $29.18 million, missing analyst expectations of $29.86 million, indicating potential challenges in meeting revenue targets. (tradingview.com)
The company's stock has declined by 38.8% since its last earnings report, reflecting investor concerns over its financial performance and future prospects. (stockinvest.us)
Barclays PLC reduced its holdings in Nektar Therapeutics by 9.1% during the fourth quarter, suggesting decreased institutional confidence in the company's stock. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 25 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NKTR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs